Knight Therapeutics Inc. (GUD.TO), Tuesday announced that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI.
The approval comes after a supplemental regulatory filing and review by ANVISA under Project Orbis for MINJUVI, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Notably, the approval is backed by findings from clinical studies, which demonstrated meaningful response rates and durable disease control in patients.
CEO Samira Sakhia commented, "The rapid review and approval under Project Orbis reflect Knight's strong regulatory capabilities and focused execution for the benefit of Knight and our partners."
Currently, Knight's stock is trading at C$6.14, up 0.66 percent on the Toronto Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.